A recent phase 1b-2 study has demonstrated that combining talquetamab and teclistamab yields a high response rate in patients with relapsed or refractory multiple myeloma. The trial, which included 94 participants, identified a recommended phase 2 regimen of talquetamab at 0.8 mg/kg and teclistamab at 3.0 mg/kg, administered biweekly. This combination therapy achieved an 80% response rate among patients receiving the recommended regimen, with 86% maintaining their response at 18 months.
However, the study also reported a high incidence of grade 3 or 4 adverse events, occurring in 96% of patients, predominantly hematologic in nature. Notably, 64% experienced severe infections. These findings suggest that while the talquetamab-teclistamab combination shows promising efficacy, careful monitoring for adverse effects is essential. Further research is warranted to optimize the balance between therapeutic benefits and potential risks in this patient population. Click for More Details
